期刊
IUBMB LIFE
卷 74, 期 12, 页码 1209-1231出版社
WILEY
DOI: 10.1002/iub.2680
关键词
bioactivation; cancer; KEAP1; mitomycin C; NRF2; oxidative stress; prodrug; stress response; synthetic lethal
资金
- Japan Agency for Medical Research and Development [JP17am0101001, JP20cm0106101]
- Japan Society for the Promotion of Science [19H05649, 19K16512]
The KEAP1-NRF2 pathway plays a crucial role in human cancer development, leading to aggressive tumors resistant to current treatment regimens. Thus, targeting NRF2-activated cancers with new therapeutic strategies is essential in overcoming treatment resistance.
The KEAP1-NRF2 pathway regulates the main inducible cellular response to oxidative and electrophilic stresses. Activating mutations in the KEAP1-NRF2 pathway occur commonly in human cancer, where they contribute to the formation of aggressive tumours that are associated with a poor prognosis for patients. An important clinical feature of these tumours is their defiance to all current anti-cancer treatment regimens, highlighting the need for the development of new therapeutic strategies to target NRF2-activated cancers. In this review, we discuss the mechanisms through which acquired NRF2 hyperactivation can result in resistance of tumours to immune checkpoint inhibitor therapies in addition to classical chemotherapeutics, and propose with examples that using a synthetic lethal strategy mediated by NRF2-target gene-dependent bioactivation of prodrugs represents a promising strategy to specifically enhance toxicity to heretofore untreatable NRF2-hyperactivated human tumours.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据